




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07D 401/12</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/56730</b> <b>(43) International Publication Date:</b> 28 September 2000 (28.09.00)
<b>(21) International Application Number:</b> PCT/US00/07462 <b>(22) International Filing Date:</b> 21 March 2000 (21.03.00) <b>(30) Priority Data:</b> 60/125,671 22 March 1999 (22.03.99) US <b>(71) Applicant:</b> ORTHO-MCNEIL PHARMACEUTICAL, INC. [US/US]; U.S. Route No. 202, Raritan, NJ 08869-0602 (US). <b>(72) Inventors:</b> COHEN, Judith, H.; 107 Citadel Court, North Wales, PA 19454 (US). JUSTUS, Michael; Lindenplatz 12B, CH-8203 Schaffhausen (CH). MARYANOFF, Cynthia, A.; 4029 Devonshire Drive, P.O. Box 239, New Hope, PA 18938 (US). ROSSLER, Armin; Grenzlandstrasse 9, D-78244 Gottmadingen (DE). SCHRODER, Fridtjof, Harmen; Im Grund 14, Ch-8442 Hettlingen (CH). SORGI, Kirk, L.; 2543 Red Gate Drive, Doylestown, PA 18901 (US). VILLANI, Frank, John, Jr.; 2 Pinewood Lane, Perkasio, PA 18944 (US). WEH, Christian; Blasen-bergstrasse 28, D-88175 Schneidegg (DE). <b>(74) Agents:</b> CIAMPORCERO, Audley, A., Jr. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).		<b>(81) Designated States:</b> AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> PROCESS FOR PREPARING [S-(R*,S*)] - $\beta$ -[[[1-[1-OXO-3- (4-PIPERIDINYL) PROPYL] -3-PIPERIDINYL] CARBONYL] AMINO] -3- PYRIDINEPROPANOIC ACID AND DERIVATIVES  <div style="text-align: center;">  </div> <p style="text-align: right;">(I)</p>		
<b>(57) Abstract</b>  A process for preparing a compound of formula (I) wherein R <sup>1</sup> and R <sup>2</sup> are independently selected from the group consisting of hydrogen, lower alkyl and halogen.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PROCESS FOR PREPARING [S-(R\*,S\*)]- $\beta$ -[[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinepropanoic acid and derivatives

5

Cross Reference to Related Applications

This application claims benefit to U. S. Provisional Application No. 60/125,671, filed on March 22, 1999.


10

Background of the Invention

Field of the Invention

15

The invention relates to a process of preparing [S-(R\*,S\*)]- $\beta$ -[[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinepropanoic acid derivatives represented by the formula



20

wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from hydrogen, lower alkyl and halogen.

25

The compounds of formula I and method of making and using the compounds of formula I are described in WO 97/41102, November 6, 1997.

Compounds of formula I are antagonists of the platelet fibrinogen receptor (GP 11b/111a antagonist).

Thus, the compounds of formula I are useful for the treatment of thrombotic disorders such as restenosis post-angioplasty, unstable/stable angina and myocardial infarction.

5

A known method of the preparation of a compound of formula I is disclosed in WO 97/41102 involving coupling of enantiomerically enriched methyl (*S*)-3-amino-3-pyridylpropanoate with *N*-(*t*-butoxycarbonyl)-(*R*)-nipecotic acid followed by removal of the *N*-*t*-butoxycarbonyl protecting group under acidic conditions and coupling with 3-(*N*-*t*-butoxycarbonyl-4-piperidyl)propionic acid. The crude ester product is then hydrolyzed using aqueous LiOH and the *N*-*t*-butoxycarbonyl amino protecting group is removed under acidic conditions with trifluoroacetic acid ("TFA"). The bis-TFA salt is isolated as a white amorphous solid.

10

15

20


A process for preparing *N*-(3-piperidinyl carbonyl)- $\beta$ -alanine derivatives is disclosed in WO 95/08536.

The current invention relates to a more efficient process of preparing compounds of formula I.

25


#### Brief Summary of the Invention

The invention relates to a process of preparing a compound of formula I




I

wherein  $R^1$  and  $R^2$  are independently selected from the group consisting of hydrogen, lower alkyl and halogen, comprising coupling 3-(*N*-benzyloxycarbonyl-4-piperidyl)propionic acid calcium salt of formula II as described herein, with (R)-(-)lower alkyl nipecotate - (+)-tartrate of formula III, as described herein to form a compound of formula IV




IV

wherein  $R^3$  is lower alkyl and Ph is phenyl, reacting the compound of formula IV to form the compound of formula V



V


reacting the compound of formula V with a compound of formula VI




VI

wherein  $R^1$  and  $R^2$  are as described above and  $R^4$  is lower alkyl or aralkyl,

to form the compound of formula VII



wherein  $R^1$ ,  $R^2$ ,  $R^4$ , and Ph are as described above,  
 reacting the compound of formula VII to form the compound  
 of formula VIII



wherein  $R^1$ ,  $R^2$ , and Ph are as described above,  
 reacting the compound of formula VIII to form the compound  
 of formula I.


In another aspect, the claimed invention relates to a  
 process of preparing the compound of formula VI,  
 preferably methyl(*S*)-3-amino-3-(3-pyridyl) propanoate, an  
 intermediate in the synthesis of a compound of formula I,  
 by classical resolution of racemic methyl 3-amino-3-(3-  
 pyridyl) propanoate using (+)-tartaric acid. This new  
 process led to a more cost effective and volume efficient  
 synthesis of enantiomerically pure methyl (*S*)-3-amino-3-  
 (3-pyridyl)propanoate in good yield and high purity.

Another aspect of the claimed invention relates to a  
 process for preparing the intermediate (R)-(-)lower alkyl

nipecotate (+) tartrate salt which involves resolving racemic ( $\pm$ ) lower alkyl nipecotate using (+) tartaric acid in an isopropyl alcohol and water mixture.

5 A further aspect of the claimed invention relates to the purification of the compound of formula I by dissolving the free base of formula I in an organic solvent and adjusting the pH in the range of from about 4 to about 12 in the presence of an organic amine base to  
10 precipitate the purified compound of formula I.

Costanzo, et al., in WO97/41102, November 6, 1997 disclose the compound of formula Ia as a free base. A further aspect of the claimed invention relates to a novel  
15 crystalline form of the compound of formula Ia.



### Detailed Description of the Invention

20 As used herein, the term "alkyl" whether used alone or as part of a substituent group, include straight and branched chains. For example, alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and the like. Unless  
25 otherwise noted, "lower" when used with alkyl means a carbon chain composition of 1-4 carbon atoms.

As used herein, unless otherwise noted, "aralkyl" shall mean any lower alkyl group substituted with an aryl group such as phenyl, naphthyl and the like.

5           The term "halogen" means fluorine, chlorine, iodine or bromine.


10           With reference to substituents, the term "independently" means that when more than one of such substituents is possible, such substituents may be the same or different from each other.

15           The term "hydrogenation catalyst" shall mean a catalyst of rhodium (Rh), palladium (Pd) or platinum (Pt) which is adsorbed on a solid support such as Rh on carbon, Pd on carbon, Pd(OH)<sub>2</sub> on carbon or Pt on carbon or unsupported such as PtO<sub>2</sub>.

20           In a preferred embodiment of the invention, the process relates to a process of preparing a compound of formula I wherein R<sup>1</sup> and R<sup>2</sup> are hydrogen.

25           The invention relates to a process of preparing a compound of formula I as more fully described in the schemes below.





SCHEME 1

As set forth in Scheme 1 above, 3-(4-pyridine)acrylic acid, a known compound, is reduced to 3-(4-piperidyl)propionic acid by catalytic hydrogenation in a basic solvent such as inorganic bases, for example, alcoholates, hydroxide, hydrogen carbonate, carbonate of alkali or earth alkali metals or ammonia; or organic bases, for example, primary, secondary, or tertiary alkylamines, in aqueous or alcoholic solution, preferably aqueous ammonia, in the presence of a rhodium catalyst, preferably rhodium on  $\text{Al}_2\text{O}_3$  at a temperature of from about room temperature to about  $95^\circ$ , preferably  $80-95^\circ\text{C}$  at a pH in the range of about 7-13, preferably about 7-8.

3-(4-Piperidyl)propionic acid is reacted with a reagent capable of placing a benzyloxy carbonyl protecting group on an amine such as N-(benzyloxy carbonyloxy) succinimide (Cb<sub>2</sub>OSu), N-benzyloxy carbonyloxy-5-norbornene-2,3-dicarboximide, or benzyl chloroformate, preferably benzyl chloroformate in a basic calcium salt, such as aqueous Ca(OH)<sub>2</sub> or calcium carbonate, preferably Ca(OH)<sub>2</sub>, at a temperature in the range of from 0 to room temperature, preferably 0-10°C and preferably at a pH in the range of about 8-14, preferably about 11-14, to form the 3-(N-benzyloxycarbonyl-4-piperidyl) propionic acid calcium salt of formula II.

The salt of formula II is reacted with (R)-(-)lower alkyl nipecotate tartrate of formula III, a known compound or compound prepared by known methods (J. Org. Chem., 1974, 39(7), 893; Eur., J. Pharmacol., 1983, 89(3-4)217), in the presence of a coupling reagent such as 1,3-dicyclohexyl carbodiimide (DCC), O-benzotriazole-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, preferably DCC, in the presence of 0 to 1 equivalents, preferably 0.1 equivalents, of an additive such as 1-hydroxybenzotriazole hydrate (HOBT) or 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (HOBT), preferably HOBT, in a solvent mixture of an organic solvent and water, such as, ethyl acetate/water or tetrahydrofuran/water or a polar organic solvent, such as dimethylformamide or 1-methyl-2-pyrrolidinone (NMP), at a temperature in the range of from 0-50°C preferably 15-25°C and at a pH in the range of from about 6-10, preferably about 6-7, to form the corresponding compound of formula IV.

The compound of formula IV is hydrolyzed in an inorganic base such as lithium hydroxide, sodium hydroxide, preferably lithium hydroxide, in an organic solvent such as THF or dioxane, at a temperature in the range of from about 0 to about 50°C, preferably 5-25°C at a pH preferably in the range of about 10 to about 13, to form the compound of formula V.

The compound of formula V is reacted with a carboxylic acid salt of the compound of formula VI, preferably the tartrate salt, in the presence of a coupling reagent such as 1,3-dicyclohexylcarbodiimide (DCC), 0-benzotriazole-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, preferably DCC, in the presence of 0 to 1 equivalents, preferably 0.1 equivalents of an additive such as 1-hydroxybenzotriazole hydrate (HOBT) or 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (HOBT), preferably HOBT, preferably DCC and HOBT, in the presence of a calcium salt such as calcium hydroxide, calcium carbonate, and the like, preferably calcium hydroxide, in an amount of at least 1 equivalent, to form the corresponding compound of formula VII, in a solvent mixture of an organic solvent and water, such as, ethyl acetate/water or tetrahydrofuran/water or a polar organic solvent, such as dimethylformamide or 1-methyl-2-pyrrolidinone (NMP) at a temperature in the range of from 0-50°C preferably 15-25°C and at a pH in the range of from about 6-10, preferably about 6-7.


Alternatively, the compound of formula V is reacted with a compound of formula VI or an inorganic salt

thereof, preferably HCl salt, a known compound or compound prepared by known methods WO 97/41102, in the presence of a coupling reagent such as 1,3-dicyclohexylcarbodiimide (DCC), 0-benzotriazole-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, preferably DCC, in the presence of 0 to 1 equivalents, preferably 0.1 equivalents of an additive such as 1-hydroxybenzotriazole hydrate (HOBT) or 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (HOBT), preferably HOBT, preferably DCC and HOBT, to form the corresponding compound of formula VII, in a polar organic solvent such as acetonitrile, DMF, NMP, preferably acetonitrile, in the presence of an organic base such as triethylamine, diisopropylethylamine (DIPEA) or 4-methylmorpholine (NMM), preferably NMM, at a temperature in the range of 0-35°C, and at a pH in the range of about 7-11, preferably in the range of about 8-10.

The compound of formula VII is reacted in an organic solvent, such as THF, dioxane, or DMF, preferably THF, in the presence of an inorganic base such as sodium hydroxide, or lithium hydroxide, preferably lithium hydroxide, at a temperature in the range of from 0-40°C, preferably 10-15°C, preferably at a pH in the range of about 8-11. The resulting mixture is acidified with an inorganic acid such as sulfuric, hydrochloric, and the like, preferably to a pH of about 3-5, to yield the corresponding compound of formula VIII. When the mixture is acidified with sulfuric acid, the acidification results in the precipitation of N,N'-bis(2,2,2-trichloro-1-hydroxyethyl)urea (DCU), which is preferably removed prior to the next step.

The compound of formula VIII is converted to the corresponding compound of formula I via catalytic hydrogenation using a hydrogenation catalyst, preferably a palladium catalyst such as Pd/C, in a polar solvent such as an alcohol, preferably methanol or ethanol, at a temperature of from 30-50°C.

The compound of formula I is purified by heating the compound of formula I in an organic solvent such as ethylacetate, methyl t-butyl ether, methanol, ethanol, n-butanol and the like, preferably n-butanol, to a temperature up to 85°, preferably 75-85°C. The solution is then cooled to a temperature in the range of about 20-30°C. An amine organic base such as triethylamine, cyclohexylamine, t-butylamine and the like, preferably t-butylamine, is added in an amount sufficient to result in a pH in the range of about 4-12, preferably about 7-11, most preferably 7.5.



SCHEME 2

As set forth in Scheme 2 above, a compound of formula IX, a known compound or compound prepared by known

methods, J. Am. Chem Soc 1957, Vol. 79, p. 159, is converted to a corresponding compound of formula X by dissolution in an organic solvent such as, methanol, isopropanol, toluene and mixtures thereof, with at least  
5 one equivalent of gaseous  $\text{NH}_3$  at a temperature in the range of from 40-100°C, preferably 60-65°C in the presence of a carboxylic acid such as acetic acid or formic acid.


The compound of formula X is reduced to the  
10 corresponding compound of formula XI, preferably by reacting with borohydride reagents such as sodium borohydride, in an organic solvent such as THF, in the presence of an organic acid such as propionic acid, benzoic acid, acetic acid, or trifluoroacetic acid (TFA),  
15 preferably acetic acid or TFA, at a temperature in the range of -5 to 10°C at a pH in the range of about 1-6.

In the case where the compound of formula X is reduced by reacting with a borohydride reagent, the  
20 reaction is quenched with an alcohol, preferably methanol and a strong acid such as hydrochloric or sulfuric, preferably hydrochloric, to afford a compound of formula XI as a salt. The amine is freed by reacting the salt of the compound of formula XI with a tertiary amine such as  
25 triethylamine, DIPEA, or NMM, preferably triethylamine, in an organic solvent such as acetonitrile, THF, or dioxane, preferably acetonitrile. The resulting tertiary amine salt is separated by conventional methods such as filtration or extraction, preferably filtration, to afford  
30 the compound of formula XI as the free amino ester.

The compound of formula XI is heated in the presence of (+)-tartaric acid, preferably 0.25 equivalents of (+)

tartaric acid, to a temperature resulting in the formation of a solution in a polar solvent, such as alcohol, for example, methanol or ethanol or an alcohol water mixture, such as methyl alcohol/water or ethyl alcohol/water, preferably ethyl alcohol/water mixture at a ratio of 90:10 to 100% ethanol, preferably at a ratio of 97:3 and cooled to a temperature in the range of 25-30°C to form the corresponding salt of formula XII.

The tartrate salt of formula XII is converted to the corresponding compound of formula VI or salt thereof, by known methods. Preferably, the salt of formula XII is reacted with at least two equivalents, preferably between 8 and 11 equivalents, of gaseous HCl, in a polar solvent, such as methanol, ethanol, isopropyl alcohol, ethyl acetate or mixture thereof, at a temperature in the range of 0-50°C, preferably at about 10°C, to form the corresponding dihydrochloride salt of formula VI. When R<sup>4</sup> is methyl, the preferred solvent is methanol.



SCHEME 3

As set forth in Scheme 3 above, the compound of formula XIII, a known compound or compound prepared by known methods (Eur. J. Pharmacol., 1983, 89(3-4), 217), is reacted with (+)tartaric acid, preferably one equivalent (+) tartaric acid in a mixture of isopropyl alcohol (IPA) and water, preferably at a ratio of 90:10 up to 100% IPA, more preferably at a ratio of 94:6, and heating to form a

solution, preferably at a temperature in the range of from 73-77°C then cooled to no less than 20°C, preferably 26-30°C, to form the corresponding salt of formula III.

5 A further aspect of the present invention is a novel crystalline forms of the compound of formula Ia, characterized by its x-ray powder diffraction pattern, utilizing a Philips PW3710 based powder diffractometer using CuK $\alpha$  radiation and the following system conditions:

- 10 a) CuK $\alpha$  radiation, 30mA, 50KV  
b) Optics  
1/12° divergence slit  
0.2 receiving slit  
15 c) Scan 5.01 to 34.97° 2 $\theta$  at a scan rate of  
0.020°/1.25 sec 2 $\theta$ /second  
d) Aluminum sample holder

20 The novel crystal form of the compound of formula Ia appears as irregular acicular particles crystals and may be characterized essentially by its X-ray diffraction pattern:

POWDER X-RAY DIFFRACTION RESULTS

Angle °2 $\theta$	d Spacing (Å)	Relative Intensity (%)
8.77	10.09	17.50
10.52	8.41	16.20
15.57	5.69	100.00
15.90	5.65	22.70
16.52	5.37	48.30
17.48	5.08	25.80
17.72	5.01	24.70
18.32	4.85	58.10
19.62	4.53	21.50
19.98	4.45	47.30



20.28	4.38	41.50
21.08	4.22	67.80
21.36	4.16	18.10
22.82	3.90	23.50
23.26	3.83	50.40
24.01	3.71	57.60
24.73	3.60	24.10
25.62	3.48	9.90
25.99	3.43	8.00
26.37	3.38	4.60
27.37	3.26	13.50
27.98	3.19	23.20
28.62	3.12	15.70
30.20	2.96	19.00
30.71	3.41	17.30
31.29	2.86	32.40
31.40	2.85	33.30
31.73	2.82	25.10
32.71	2.74	12.40
33.84	2.65	9.70
34.55	2.60	10.20

The following examples describe the invention in greater detail and are intended to illustrate the invention, but not to limit it.

#### EXAMPLE 1

##### 3-(4-Piperidyl)propionic acid

3-(4-pyridine)acrylic acid (18 kg) was added to 75 kg of water. The resulting suspension was stirred and neutralized (pH 7.5) with 6.8 kg of aqueous ammonia (25%). A slurry of Rh/Al<sub>2</sub>O<sub>3</sub> (0.9 kg) in 5 kg of water was added to the reaction mixture, which was then made inert under nitrogen. The mixture was hydrogenated under a pressure of 3-3.5 bar at 85-95 °C. After eight hours, when no further change in pressure was observed, the mixture was cooled to 25-35 °C. The catalyst was filtered and washed

with 4.0 kg of water. Ammonia and most of the water in the reaction mixture were removed under vacuum at 80-90 °C, and the product began to precipitate. Acetonitrile (116 kg) was added and then the mixture was concentrated (ca. 50%) under vacuum. Additional acetonitrile (57.1 kg) was added to aid in crystallization and the reaction mixture was stirred for 1-4 hours at 15-25 °C until precipitation of the product was complete. The product was centrifuged and oven dried under vacuum at 45-55 °C to afford 19.1 kg (100%) of the title compound.

#### EXAMPLE 2

Di 3-(*N*-Benzyloxycarbonyl-4-piperidyl)propionic acid  
calcium salt

3-(4-Piperidyl)propionic acid (20.0 g, 0.12 mol) and calcium hydroxide (14.1 g, 0.19 mol) were suspended in 47 g water and 195 g acetonitrile at 15-25°C and then cooled to 0-10°C. Benzyl chloroformate (23.9 g, 0.14 mol) was added within 30 minutes and the reaction stirred at 0-5°C for 2 h. The product precipitated during the reaction and was isolated by filtration to afford the title compound in 95% yield.

#### EXAMPLE 3

(*R*)-(-)-Ethyl Nipecotate tartrate

L-(+)-Tartaric acid (47.74 g, 318 mmol) was suspended in 265 g of isopropyl alcohol and 16.91 g of water. The mixture was heated to 60-65°C to afford a homogeneous solution. One equivalent of (±)-ethyl nipecotate (50 g,

318 mmol) was added while the temperature was maintained at or below 75°C. The mixture was stirred at 70-75°C for 20-30 minutes, then cooled to 60°C over 60 minutes. Seed crystals of (R)-

5 (-)-ethyl nipecotate -L-(+)-tartrate (25 mg, 0.08 mmol) were added and the reaction was cooled to 26-30°C over three hours. The temperature was maintained at 26-30°C for 30 minutes until precipitation was complete. The product was isolated (62.0 g, 94.8% de) and washed twice  
10 with a mixture of isopropyl alcohol (21.05 g) and water (1.34 g). The crude product was slurried in a mixture of isopropyl alcohol (188 g) and water (12 g) at 73-77°C. After stirring for 10-20 minutes, the suspension was cooled to 26-30°C. Temperatures exceeding 30°C will  
15 result in less yield, while a temperature of less than 25°C resulted in de <98%. The product was isolated by filtration and washed twice with a mixture of isopropyl alcohol (21.05 g) and water (1.34 g). This afforded the title compound as a white powder in 72% yield, 98.8% de.

#### EXAMPLE 4

(R)-1-[3-(1-benzyloxycarbonyl-4-piperidyl)-propionyl]-3-piperidinecarboxylic acid

25 3-(N-Benzyloxycarbonyl-4-piperidyl)propionic acid calcium salt (21.9 g, 32.2 mmol), (R)-ethyl nipecotate (21.7 g, 70.8 mmol), and hydroxy benzyltriazole (HOBT) (1.30 g, 9.65 mmol) were suspended in water (40 g) and THF  
30 (80 g). The resulting suspension was adjusted to pH 7 with Ca(OH)<sub>2</sub>. Ca-tartrate precipitated and was collected by filtration and washed with 10 g THF. To the filtrate was added slowly a solution of DCC (19.9 g, 96.5 mmol) in 40 g

of THF at 0-5°C. The reaction mixture was warmed slowly to 20-25 °C and N,N-dichlorourethane (DCU) precipitated. After 4h, the DCU was removed by filtration and washed with 8 g of THF. The filtrate was cooled to 0-5 °C and lithium hydroxide (6.67 g, 159.0 mmol) in 60.38 g of water was added at 0-5 °C. The pale yellow solution was warmed to ambient temperature. After 3h, the solvent was removed by distillation under vacuum at or below 55 °C. Ethyl acetate (45.4 g) was added and the pH was adjusted to exactly 4.0 with ca. 18.6 g of concentrated HCl. DCU precipitated and was filtered from the mixture. The layers were separated and the aqueous layer was washed twice with 31.8 g of ethyl acetate. The combined organic layers were washed twice with a solution of 15.8 g NaCl in 47.2 g of water. The ethyl acetate layer was separated and the solvent was removed by distillation under vacuum at or below 55 °C. The product remained as a thick pulp. MTBE (70.8 g) was added and the suspension was stirred for 30 minutes at 45-50 °C, then cooled to 15-25 °C and stirred for one hour until crystallization was complete. The product was centrifuged and washed with 6.3 g of MTBE, then dried under vacuum at 40-50 °C to afford the title compound in 92% yield and >98% ee.

#### EXAMPLE 5

Methyl (S)-3-Amino-3-(3-pyridyl)propanoate dihydrochloride

Two separate procedures were developed to synthesize this compound. The first procedure (A) involved two steps for the production of enantiomerically pure methyl(s)-3-amino-3-(3-pyridyl)propanoate dihydrochloride via NaBH<sub>4</sub> reduction. The second procedure (B) involved three steps

for the production of enantiomerically pure methyl(S)-3-amino-3-(3-pyridyl)propanoate dihydrochloride via hydrogenation.

5 Procedure A:

Methyl 3-Amino-3-(3-pyridyl)-2-propenoate

A suspension of methyl nicotinoylacetate dihydrochloride (50.0 g, 0.23 mol, dried) and sodium acetate (19.0 g, 0.23 mol) in glacial acetic acid (1.4 g, 0.02 mol), toluene (50 g), and methanol (50 g) was heated  
10 to 60-65°C. Ammonia (14.0 g, 0.82 mol) was bubbled through the suspension. After four hours, no starting material was present by HPLC. Two-thirds of the solvents were removed by distillation. The solution was stirred at  
15 0°C for one hour, and the precipitate was collected by filtration and dried to yield 83% of methyl 3-amino-3-(3-pyridyl)-2-propenoate. The crude product was used as is without further purification.

20 Methyl 3-Amino-3-(3-pyridyl)propanoate dihydrochloride

Glacial acetic acid (526.9g, 8.78mol) was added dropwise at <-5°C to a suspension of methyl 3-amino-3-(3-pyridyl)-2-propenoate (0.45mol) and sodium borohydride (44.3g, 1.17mol) in THF (500 g) and the resulting reaction  
25 mixture was stirred at -5-0°C. After 5 h, methanol (600 g) was added dropwise to the solution at -5-0°C. After 0.5 hours, HCl (163 g, 4.47 mol) was bubbled through the solution and stirred at 0°C. After 8 h, the white precipitate was filtered off and dried at 40°C to yield  
30 101.6 g (89%) of methyl 3-Amino-3-(3-pyridyl)propanoate dihydrochloride.

Procedure B:

## Methyl 3-Amino-3-(3-pyridyl)-2-propenoate

Methyl nicotinoylacetate (88 g, 0.5 mol) was dissolved in toluene (200 g), isopropyl alcohol (200 g), and formic acid (98-100%, 1.22 g, 0.03 mol) and heated to 60-65°C. Gaseous ammonia (23 g, 1.35 mol) was bubbled through the solution for 15 minutes. The white suspension was stirred at 65°C until a homogeneous solution formed. The solution was stirred for two hours at 65°C and then concentrated (ca. 200 g) at 65°C. The residue was cooled to -5°C with stirring and methyl 3-amino-3-(3-pyridyl)-2-propenoate crystallized as colorless needles. The process of reducing the volume to 50% followed by cooling was repeated three times with the mother liquors. Filtration, washing with toluene, and drying at 30 °C resulted in 77.74 g (88.8%) of methyl 3-amino-3-(3-pyridyl)-2-propenoate as colorless crystals.

## Methyl 3-Amino-3-(3-pyridyl)propanoate dihydrochloride

Dry palladium on charcoal (0.54 g, manufactured by Degussa, 5% Pd/C) was added to a solution of methyl 3-Amino-3-(3-pyridyl)-2-propenoate (5.4 g, 30 mmol) in dry acetic acid (13 g) in a 450 ml Pyrex high-pressure bottle. The reaction mixture was hydrogenated at 3-3.2 bar. After 1.5-2 h, the catalyst was filtered and washed with 20 g of isopropyl alcohol until the wash solvent was no longer yellow. Gaseous HCl (10.6 g, 0.3 mol) was bubbled through the stirred filtrate at 5-15°C. The suspension was cooled to 0-5°C and stirred for two hours. The resulting white precipitate was filtered, washed with 5 g of isopropyl alcohol, and dried at 45°C to yield 5.95 g (78.4%,) of methyl 3-Amino-3-(3-pyridyl)propanoate dihydrochloride.

EXAMPLE 6

Methyl (S)- 3-amino-3-(3-pyridyl)propanoate  
dihydrochloride

Racemic methyl 3-amino-3-(3-pyridyl)propanoate dihydrochloride (150 g, 0.563 mol) was suspended in acetonitrile (425 g). Triethylamine (125.3 g, 1.239 mol) was added dropwise while the temperature was maintained at 35°C or less. The reaction was stirred for a minimum of two hours at 20°C then cooled to 5°C. After 0.5 hours the resulting precipitate was centrifuged and washed with 50 g of acetonitrile. The acetonitrile was removed by distillation at 40-45°C to afford crude free base of methyl 3-amino-3-(3-pyridyl)propanoate dihydrochloride. The free base (ca. 105 g) was dissolved in 80 g of ethanol. A solution of (+)-tartaric acid (21.1 g, 0.141 mol) in 80 g of ethanol and 5 g of water was added. The reaction mixture was stirred for 4 hours at 20-23°C. The suspension was cooled slowly to 10-15°C, then stirred for an additional two hours. The precipitate was filtered off and washed with 30 g of ethanol.

The crude tartrate salt was slurried at 35-40°C for two hours in a mixture of 150 g of ethanol and 4.6 g of water. The mixture was stirred for 0.5 hours at 25°C. The resulting precipitate was isolated and washed with 30 g of ethanol. Up to three slurries may be necessary to achieve a > 98% de. The precipitate was suspended in methanol (100 g) and a minimum of 10 equiv. HCl gas (51.3 g, 1.408 mol) was added. The reaction mixture was stirred at 22-28°C until the reaction was complete by HPLC. Ethyl

acetate (160 g) was added and the reaction mixture was stirred at 0-5°C for three hours. The precipitate was filtered and washed with 30 g of cold (0-5°C) methanol. The product was dried under vacuum at 35-45 °C to yield 39.46 g of the title compound as a white solid (28%, 55% of the desired S-enantiomer).

#### EXAMPLE 7

[S-(R\*,S\*)]-β-[[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoic acid

(R)-1-[3-(1-benzyloxycarbonyl-4-piperidyl)-propionyl]-3-piperidinecarboxylic acid (60 kg, 149 mol) and HOBT (1.98 kg, 14.8 mol) were suspended in acetonitrile (164 kg) at 0-5°C. NMM (33.2 kg, 328.5 mol) and methyl (S)-3-amino-3-(3-pyridyl)propanoate dihydrochloride (39.2 kg, 154.9 mol) were added to the reaction mixture. After 1 h, a solution of DCC (37.2 kg, 180.3 mol) in acetonitrile (117 kg) was added at 0-5°C. The mixture was warmed to 20-25°C and stirred for 12 hours. The suspension was cooled to 0-5°C and the precipitated DCU was filtered off and washed with 81 kg of pre-cooled ethyl acetate. The solvent was distilled from the filtrate, and the residual oil was dissolved twice in 50 kg of ethyl acetate and the solvent removed. The resulting oil was dissolved in 162 kg of ethyl acetate and washed three times with a solution of 6.3 kg of NaHCO<sub>3</sub> in 120 kg of water to remove excess HOBT. The solvent was removed from the organic layer and the resulting oil and/or foam was dissolved twice in 50 kg of THF and evaporated to dryness to afford methyl [S-(R\*,S\*)]-β-[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-



piperidinyl]carbonyl]amino]-3-pyridine propanoate as an oil.

Crude methyl [S-(R\*,S\*)- $\beta$ -[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoate was dissolved in 163 kg of THF at 45°C. The clear solution was cooled to 0-5°C and within 30 to 60 minutes a solution of lithium hydroxide monohydrate (14.3 kg, 340.8 mol) in 151 kg of water was added to the reaction mixture. The pale yellow solution was stirred for 2 h at 20-25°C. HCl (36-38%, 38 kg) was added to achieve a pH of 4.1. NaCl (7.2 kg) was added and the layers were separated. The organic layer was washed twice with a solution of 36.4 kg of NaCl in 72.6 kg of water. The organic layers were distilled and the resulting oil was dissolved in 75 kg of THF. The solvent was removed until a water content of <2% was achieved. The precipitated inorganic salts were removed and washed with 9 kg of THF. The filtrate was evaporated under vacuum at 45°C to afford [S-(R\*,S\*)- $\beta$ -[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoic acid as an oil.

Crude [S-(R\*,S\*)- $\beta$ -[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoic acid was dissolved in 312 kg of methanol. A suspension of 60 kg of methanol and 15 kg of slurried Pd/C (wet) was added to the reaction mixture, which was then hydrogenated under pressure (2-3 bar) with stirring at 38-42°C. When the hydrogenation was finished, the catalyst was filtered through Hyflo SuperCel and washed with 39 kg of methanol.

The filtrate was reduced to a colorless oil under reduced pressure at 40-50°C. The crude product was dissolved in 60 kg of *n*-butyl alcohol and concentrated to an oil, which began to bubble or foam. The crude product was slurried in 756 kg of *n*-butyl alcohol and heated to 75-85°C for 15-20 minutes, then cooled to 20-30°C. *t*-Butylamine (0.7 kg) was added (pH 7.5) and the reaction was stirred. The reaction mixture was cooled to 0-5°C and stirred for an additional hour. The precipitate was isolated, washed with 102 kg of MTBE, and dried under vacuum at 60-80°C to yield 36 kg (58%) of the title compound as a white crystalline solid.

#### Example 8

[S-(R\*,S\*)]-β-[[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoic acid

(R)-1-[3-(1-benzyloxycarbonyl-4-piperidyl)-propionyl]-3-piperidinecarboxylic acid (1kg, 2.48 mol), methyl (*S*)-3-amino-3-(3-pyridyl)propanoate tartrate (where the tartrate is present as a hemi-tartrate) (0.7kg, 2.73 mol) and HOBt (38g, 0.25 mol) were added to a reaction vessel. To the mixture was added a previously prepared cold solution (0-5°C) of KH<sub>2</sub>PO<sub>4</sub> (96.8g, 0.71 mol) and Na<sub>2</sub>HPO<sub>4</sub> (69.2g, 0.49 mol) in water (3kg) and THF (2kg). The pH was then adjusted to 6.0-6.4 using calcium hydroxide (110g). The resulting suspension was cooled to 0-5°C and a solution of DCC (564g, 2.73 mol) in THF (1kg) was added. The mixture was stirred for 1h at 0-5°C, warmed to 20-25°C and stirred for 4h. The suspension was cooled to 0-5°C and ethyl acetate (2kg) was added. After 15 minutes, the


precipitate (a mixture of DCU and calcium tartrate) was filtered off and washed with pre-cooled THF (1kg). The phases were separated and the organic phase was washed with 5% NaHCO<sub>3</sub> (1kg). The organic phase was concentrated at 40-50°C, the residual oil was dissolved in THF (1kg) and evaporated to dryness to afford methyl [S-(R\*,S\*)-β-[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoate as an oil.

Crude methyl [S-(R\*,S\*)-β-[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoate was dissolved in THF (1.4kg) at 45°C. The clear solution was cooled to 0-5°C. Within 30-90 min, a solution of lithium hydroxide monohydrate (182g, 4.21 mol) in water (1.9kg), cooled to 5°C, was added to the reaction mixture. The solution was stirred for 0.5h at 0-5°C, warmed to 20-25°C and stirred for an additional 1h. The reaction mixture was cooled to 0-5°C and treated with a solution of sulfuric acid (250g) in water (1.14kg) to achieve a pH of 3.9-4.1. The precipitated DCU was collected by filtration and washed with THF (400g). The resulting phases were separated and the organic phase washed with a saturated NaCl solution (1kg). The organic layer was distilled and the resulting oil dissolved in THF (2kg). The solvent was removed until a water content of <2% was achieved. The precipitated inorganic salts were removed. The filtrate was concentrated and the resulting oil dissolved in MeOH (2kg). The solution was evaporated under vacuum at 45°C to afford [S-(R\*,S\*)-β-[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoic acid as an oil.

Crude [S-(R\*,S\*)- $\beta$ -[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoic acid was dissolved in a suspension of Pd/C (261g) in MeOH (3kg). The reaction mixture was hydrogenated under pressure (2-3 bar) with stirring at 30-40°C. After 6h, the catalyst was filtered through Hyflo SuperCel and washed with methanol (1.04kg). The filtrate was concentrated under reduced pressure at 40-50°C. The crude product was dissolved in n-butyl alcohol (1kg) and concentrated to an oil. The crude product was taken up in n-butyl alcohol (1.7kg) and heated to 75-85°C for 1-3h, then cooled to 20-30°C for 2-3h. The resulting suspension was cooled to 0-5°C and stirred for an additional 1h. The precipitate was isolated, washed with MTBE (1.7kg), and dried under vacuum at 60-80°C to yield 36 kg (53%) of the title compound as a white crystalline solid.


CLAIMS:

1. A process for preparing a compound of formula I




I

wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from the group consisting of hydrogen, lower alkyl and halogen, comprising reacting the salt of formula II




II

with the salt of formula III




III

at a pH in the range of about 6 to 10 to form the compound of formula IV




IV


reacting the compound of formula IV to form the compound of formula V




reacting the compound of formula V with a compound of formula VI



at a pH in the range of about 7 to 11  
to form the compound of formula VII




reacting the compound of formula VII to form the compound of formula VIII




and reacting the compound of formula VIII with hydrogen in the presence of a hydrogenation catalyst to form the compound of formula I.

2. The process of claim 1, wherein in the compound of formula I  $R^1$  and  $R^2$  are hydrogen.


3. A process for preparing a compound of formula VI



5 wherein  $R^1$  and  $R^2$  are independently selected from hydrogen, lower alkyl and halogen, and  $R^4$  is lower alkyl or aralkyl, or salt thereof comprising reacting a compound of formula XI



10 with (+)tartaric acid to form the salt of formula XII




and reacting the salt of formula XII to form the compound of formula VI or salt thereof.

4. The process of claim 3, wherein in the compound of formula XI  $R^4$  is methyl and the (+)tartaric acid is present in an amount of 0.25 equivalents.


5. The process of claim 4, wherein in the compound of formula VI,  $R^1$  and  $R^2$  are hydrogen and  $R^4$  is methyl.

6. The process of claim 4, wherein the salt of formula XII is reacted with gaseous HCl in methanol to form the dihydrochloride salt of formula VI.

7. A process of preparing a salt of formula III



wherein R<sup>3</sup> is lower alkyl comprising reacting a compound of formula XIII




XIII

with (+)tartaric acid in a mixture of isopropyl alcohol and water.

8. The process of claim 7, wherein in the salt of formula III, R<sup>3</sup> is ethyl.

9. The process of claim 8, wherein in the mixture of isopropyl alcohol and water the isopropyl alcohol is present in a ratio of from 90 percent isopropyl alcohol to 10 percent water to 100 percent isopropyl alcohol.

10. A process of purifying a compound of formula I



I

wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from the group consisting of hydrogen, lower alkyl and halogen,



comprising reacting the free base of formula I at a pH in the range of from about 4 to 12 in the presence of an organic amine base.


11. The process of claim 10, wherein in the compound of formula I  $R^1$  and  $R^2$  are hydrogen.

12. The process of claim 11, wherein the organic amine base is triethylamine, cyclohexylamine, or t-butylamine and the reaction is carried out at a pH in the range of from about 7 to 11.

13. The process of claim 12, wherein the reaction is carried out at a pH of 7.5.


14. The process of claim 13, wherein the organic amine base is t-butylamine.

15. A process for preparing a compound of formula VIII



VIII


wherein  $R^1$  and  $R^2$  are independently selected from the group consisting of hydrogen, lower alkyl and halogen, comprising reacting a compound of formula V



V

wherein Ph is phenyl,

with a carboxylic acid salt of a compound of formula VI



VI

wherein  $R^1$  and  $R^2$  are independently selected from the group consisting of hydrogen, lower alkyl and halogen, and  $R^4$  is lower alkyl or aralkyl,


in the presence of a calcium salt, in an amount equal to at least 1 equivalents, at a pH in the range of about 6-10.

16. The process of Claim 15, wherein the carboxylic acid salt of the compound of formula VI is tartrate salt.

17. The process of Claim 15, wherein the calcium salt is calcium hydroxide.

18. The process of Claim 15, wherein the pH is in the range of about 6-7.

19. A crystalline form of the compound of formula Ia



Ia

characterized essentially by the following X-ray diffraction pattern:

Angle °2θ	d Spacing (Å)	Relative Intensity (%)
8.77	10.09	17.50
10.52	8.41	16.20
15.57	5.69	100.00
15.90	5.65	22.70
16.52	5.37	48.30
17.48	5.08	25.80
17.72	5.01	24.70
18.32	4.85	58.10
19.62	4.53	21.50
19.98	4.45	47.30
20.28	4.38	41.50
21.08	4.22	67.80
21.36	4.16	18.10
22.82	3.90	23.50
23.26	3.83	50.40
24.01	3.71	57.60
24.73	3.60	24.10
25.62	3.48	9.90
25.99	3.43	8.00
26.37	3.38	4.60
27.37	3.26	13.50
27.98	3.19	23.20
28.62	3.12	15.70
30.20	2.96	19.00
30.71	3.41	17.30
31.29	2.86	32.40
31.40	2.85	33.30
31.73	2.82	25.10
32.71	2.74	12.40
33.84	2.65	9.70
34.55	2.60	10.20

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/07462

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	WO 99 21832 A (ORTHO-MCNEIL PHARMACEUTICAL, INC.) 6 May 1999 (1999-05-06) page 6 -page 9	1-19
A	WO 97 41102 A (ORTHO PHARMACEUTICAL CORPORATION) 6 November 1997 (1997-11-06) cited in the application page 7 -page 20	1-19
A	WO 97 33869 A (FUJISAWA PHARMACEUTICAL CO., LTD.) 18 September 1997 (1997-09-18) page 3 -page 4	1-19
A	WO 95 25091 A (ORTHO PHARMACEUTICAL CORPORATION) 21 September 1995 (1995-09-21) page 5 -page 18	1-19
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 July 2000

Date of mailing of the international search report

20/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Kyriakakou, G

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/07462

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 08536 A (FUJISAWA PHARMACEUTICAL CO., LTD.) 30 March 1995 (1995-03-30) cited in the application claim 13 ---	1-19
A	WILLIAM J. HOEKSTRA ET AL.: "solid-phase parallel synthesis applied to lead optimization: Discovery of potent analogues of the GPIIb/IIIa antagonist RWJ-50042" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , vol. 6, no. 20, 1996, pages 2371-2376, XP004135841 the whole document ---	1-19
A	WILLIAM J. HOEKSTRA ET AL.: "solid phase synthesis via N-terminal Attachment to the 2-chlorotrityl Resin" TETRAHEDRON LETTERS , vol. 38, no. 15, 1997, pages 2629-2632, XP004058290 the whole document -----	1-19

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/07462

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9921832 A	06-05-1999	AU 1107299 A	17-05-1999
WO 9741102 A	06-11-1997	AU 2816697 A	19-11-1997
		BG 102966 A	30-11-1999
		CA 2258701 A	06-11-1997
		CZ 9803488 A	11-08-1999
		EP 0923555 A	23-06-1999
		PL 329695 A	12-04-1999
		SK 149798 A	08-10-1999
WO 9733869 A	18-09-1997	CA 2248809 A	18-09-1997
		EP 0888302 A	07-01-1999
WO 9525091 A	21-09-1995	AT 180470 T	15-06-1999
		AU 703397 B	25-03-1999
		AU 2119195 A	03-10-1995
		CA 2163027 A	21-09-1995
		CN 1128022 A	31-07-1996
		DE 69509875 D	01-07-1999
		DE 69509875 T	09-12-1999
		EP 0746545 A	11-12-1996
		ES 2131313 T	16-07-1999
		FI 955498 A	15-01-1996
		GR 3030566 T	29-10-1999
		HU 74871 A	28-02-1997
		JP 9510453 T	21-10-1997
		NO 954609 A	05-01-1996
		NZ 283209 A	27-04-1998
		RU 2135470 C	27-08-1999
		SI 746545 T	30-04-2000
		US 5770575 A	23-06-1998
		ZA 9502171 A	16-09-1996
WO 9508536 A	30-03-1995	AU 684547 B	18-12-1997
		AU 7665794 A	10-04-1995
		CN 1116847 A,B	14-02-1996
		EP 0669912 A	06-09-1995
		HU 73174 A	28-06-1996
		IL 111036 A	14-07-1999
		ZA 9407350 A	10-05-1995
		JP 2998698 B	11-01-2000
		JP 10072490 A	17-03-1998
		JP 2713246 B	16-02-1998
		JP 8053415 A	27-02-1996
		JP 2000103783 A	11-04-2000